Qurient Co

Qurient Co Financial Leverage

The Financial Leverage (Equity Multiplier) of Qurient Co (115180.KQ) as of Oct 29, 2026 is 1.82. In the previous year, Financial Leverage (Equity Multiplier) was 1.14 — a change of 59.96% (higher).

Financial Leverage

1.82

YoY

59.96%

Last updated:

Financial Leverage (Equity Multiplier) of Qurient Co is 2025 1.82 . Financial Leverage (Equity Multiplier) of Qurient Co was 2024 1.14 . It decreases by 59.96% higher compared to the previous year.

The Qurient Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.10 KRW
Jan 1, 2019
1.18 KRW
Jan 1, 2020
1.08 KRW
Jan 1, 2021
1.12 KRW
Jan 1, 2022
1.24 KRW
Jan 1, 2023
1.13 KRW
Jan 1, 2024
1.14 KRW
Jan 1, 2025
1.82 KRW
The Qurient Co Financial Leverage history
YEARFinancial LeverageYoY
1.82+59.96%
1.14+1.09%
1.13-9.24%
1.24+11.11%
1.12+3.89%
1.08-8.93%
1.18+7.68%
1.10+1.61%
1.08+0.11%
1.08-19.16%
1.33-352.86%
-0.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Qurient Co Stock analysis

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Qurient Co stock

Financial Leverage (Equity Multiplier) of Qurient Co is 1.82 in 2025.

Financial Leverage (Equity Multiplier) of Qurient Co changed from 1.14 to 1.82, representing a 59.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Qurient Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Qurient Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Qurient Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Qurient Co